Zinc Acetate Lozenges May Improve the Recovery Rate of Common Cold Patients: An Individual Patient Data Meta-Analysis
- PMID: 28480298
- PMCID: PMC5410113
- DOI: 10.1093/ofid/ofx059
Zinc Acetate Lozenges May Improve the Recovery Rate of Common Cold Patients: An Individual Patient Data Meta-Analysis
Abstract
Background: A previous meta-analysis of 3 zinc acetate lozenge trials estimated that colds were on average 40% shorter for the zinc groups. However, the duration of colds is a time outcome, and survival analysis may be a more informative approach. The objective of this individual patient data (IPD) meta-analysis was to estimate the effect of zinc acetate lozenges on the rate of recovery from colds.
Methods: We analyzed IPD for 3 randomized placebo-controlled trials in which 80-92 mg/day of elemental zinc were administered as zinc acetate lozenges to 199 common cold patients. We used mixed-effects Cox regression to estimate the effect of zinc.
Results: Patients administered zinc lozenges recovered faster by rate ratio 3.1 (95% confidence interval, 2.1-4.7). The effect was not modified by age, sex, race, allergy, smoking, or baseline common cold severity. On the 5th day, 70% of the zinc patients had recovered compared with 27% of the placebo patients. Accordingly, 2.6 times more patients were cured in the zinc group. The difference also corresponds to the number needed to treat of 2.3 on the 5th day. None of the studies observed serious adverse effects of zinc.
Conclusions: The 3-fold increase in the rate of recovery from the common cold is a clinically important effect. The optimal formulation of zinc lozenges and an ideal frequency of their administration should be examined. Given the evidence of efficacy, common cold patients may be instructed to try zinc acetate lozenges within 24 hours of onset of symptoms.
Keywords: common cold; meta-analysis; randomized controlled trials; respiratory tract infections; zinc acetate..
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
Similar articles
-
Zinc for prevention and treatment of the common cold.Cochrane Database Syst Rev. 2024 May 9;5(5):CD014914. doi: 10.1002/14651858.CD014914.pub2. Cochrane Database Syst Rev. 2024. PMID: 38719213
-
Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis.Br J Clin Pharmacol. 2016 Nov;82(5):1393-1398. doi: 10.1111/bcp.13057. Epub 2016 Jul 28. Br J Clin Pharmacol. 2016. PMID: 27378206 Free PMC article.
-
Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage.JRSM Open. 2017 May 2;8(5):2054270417694291. doi: 10.1177/2054270417694291. eCollection 2017 May. JRSM Open. 2017. PMID: 28515951 Free PMC article.
-
The role of zinc lozenges in treatment of the common cold.Ann Pharmacother. 1998 Jan;32(1):63-9. doi: 10.1345/aph.17128. Ann Pharmacother. 1998. PMID: 9475824 Review.
-
Zinc lozenges as cure for the common cold--a review and hypothesis.Med Hypotheses. 2010 Mar;74(3):482-92. doi: 10.1016/j.mehy.2009.10.017. Epub 2009 Nov 10. Med Hypotheses. 2010. PMID: 19906491 Free PMC article. Review.
Cited by
-
Shortcomings in the Cochrane review on zinc for the common cold (2024).Front Med (Lausanne). 2024 Oct 16;11:1470004. doi: 10.3389/fmed.2024.1470004. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39478818 Free PMC article. No abstract available.
-
Modulation of T-Cell-Dependent Humoral Immune Response to Influenza Vaccine by Multiple Antioxidant/Immunomodulatory Micronutrient Supplementation.Vaccines (Basel). 2024 Jul 4;12(7):743. doi: 10.3390/vaccines12070743. Vaccines (Basel). 2024. PMID: 39066381 Free PMC article.
-
Zinc for prevention and treatment of the common cold.Cochrane Database Syst Rev. 2024 May 9;5(5):CD014914. doi: 10.1002/14651858.CD014914.pub2. Cochrane Database Syst Rev. 2024. PMID: 38719213
-
Novel antioxidant protein target therapy to counter the prevalence and severity of SARS-CoV-2.Front Immunol. 2024 Jan 3;14:1241313. doi: 10.3389/fimmu.2023.1241313. eCollection 2023. Front Immunol. 2024. PMID: 38235136 Free PMC article. Review.
-
Vitamin D and Zinc Supplementation to Improve Treatment Outcomes among COVID-19 Patients in India: Results from a Double-Blind Randomized Placebo-Controlled Trial.Curr Dev Nutr. 2023 Jul 11;7(8):101971. doi: 10.1016/j.cdnut.2023.101971. eCollection 2023 Aug. Curr Dev Nutr. 2023. PMID: 37560461 Free PMC article.
References
-
- Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev 2013; 6:CD001364. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
